Biotech

International pharmaceutical giant BeOne establishes an Israeli branch. Meanwhile, a new study links nighttime eating to liver disease, and biotech firm Nano24 reports clinical trial success.

Israeli biotech firm IdentifAI Genetics raised $7 million in a Sydney IPO, with shares surging 86% to a $54 million market cap as the company expands early prenatal testing.

Pluri has entered into a securities purchase agreement with a healthcare-focused institutional investor. Under the deal, the investor will acquire 2,228,940 ordinary shares at a price of $1.50 per share.

The biomed company of the former BrainsWay CEO, which developed a cancer treatment, will list its shares for trading on the local stock exchange as well. After a 300% jump in the last year, the company's shares are trading at a valuation of $1.2 billion.

QuantHealth, a company developing AI-based simulations for clinical trials, has raised $45 million in a Series B funding round. The total amount raised by the company has now reached $75 million.

Maor Shlomo, the founder of BASE44, has announced the establishment of a private fund to invest in startups developing cancer treatments. The decision follows the personal loss of his mother to the disease.